Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Real-world study of sintilimab + bevacizumab + chemotherapy after EGFR-TKI failure in EGFR-mutated non-squamous NSCLC
ChiCTR2500102697Phase 4Not yet recruiting
- Sponsor
- Meishan City People's Hospital
- Start
- May 2025
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of sintilimab and bevacizumab in non-small cell lung cancer (NSCLC), sponsored by Meishan City People's Hospital. Primary endpoints: Objective response rate and Progression-free survival. Planned start May 2025; status: not yet recruiting.
02
Drugs
sintilimabbevacizumab
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on ChiCTR2500102697.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2500102697.